





碧云天生物技术/Beyotime Biotechnology 订货热线: 400-1683301或800-8283301 订货e-mail: order@beyotime.com 技术咨询: info@beyotime.com 网址: http://www.beyotime.com

人参皂苷Rg1 (98%, HPLC)

| 产品编号 | 产品名称 | 包装 |
|--------------|----------------------|------------|
| SM6040-10mM | 人参皂苷 Rg1 (98%, HPLC) | 10mM×0.2ml |
| SM6040-25mg | 人参皂苷 Rg1 (98%, HPLC) | 25mg |
| SM6040-100mg | 人参皂苷 Rg1 (98%, HPLC) | 100mg |

产品简介:

▶ 化学信息:

| 中文名 | 人参皂苷Rg1 | | |
|--------|---|--|--|
| 英文名 | Ginsenoside Rg1 | | |
| 中文别名 | - | | |
| 英文别名 | Ginsenoside A2; Panaxoside A; Sanchinoside C1; | | |
| 央义加石 | Panaxoside Rg1 | | |
| 来源 | 人参 <i>Panax ginseng</i> C. A. Meyer | | |
| 化合物类型 | 萜类(Terpenoids)>三萜>达玛烷型四环三萜皂苷 | | |
| 化学式 | C ₄₂ H ₇₂ O ₁₄ | | |
| 分子量 | 801.01 | | |
| CAS号 | 22427-39-0 | | |
| 纯度 | 98%, HPLC | | |
| 溶剂/溶解度 | DMSO: ≥ 100 mg/ml (124.84 mM) | | |
| ※流而41 | 10mg加入1.25ml DMSO, 或者每8.01mg加入1ml | | |
| 溶液配制 | DMSO,配制成10mM溶液。 | | |

生物信息

| Ī | | Ginsenoside Rg1 is one of the major active components of ginseng. Ginsenoside Rg1 display promising effects by reducing cerebral Aβ levels. Ginsenoside Rg1 also reduces NF-κB nuclei | | | | | |
|---|-----------------------|---|--------------------------------|-----------------------|--------------------|-------------------|--|
| | 产品描述 | | | | | | |
| Ĺ | | translocation. | | | | | |
| Į | 信号通路 | - | | | | | |
| | 靶点 | Αβ1-42 | NF-κB nuclear translocation | р-ІкВа | p-p65 | - | |
| | IC_{50} | - | - | - | - | - | |
| Ī | | Ginsenoside Rg1 | promotes the proli | feration and differen | entiation of human | dental pulp cells | |
| | | (hDPCs). The proliferative ability of hDPCs in Ginsenoside Rg1 is significantly enhanced (p<0.05), | | | | | |
| | | especially in the Ginsenoside Rg1 (5 µM) group. ALP activity and gene expressions of DSPP and | | | | | |
| | H-H-TTI- S | DMP1 are increased in the induction group, Ginsenoside Rg1 group, and their combination group | | | | | |
| | 体外研究 | compared with the control group (p<0.05). In the RAW264.7 cells stimulated by lipopolysaccharides | | | | | |
| | | (LPS), the level of p-IκBα and p-p65 is significantly higher than in controls and PPAR-γ levels are | | | | | |
| | | significantly lower. Treatment with Rg1 vitro inhibits IκBα phosphorylation, reduces NF-κB | | | | | |
| | | nuclear translocation and upregulates PPAR-γ expression. | | | | | |
| | | In the inflamed joints of adjuvant-induced arthritis (AIA) rats, the level of p-IκBα and p-p65 is | | | | | |
| | | significantly higher than in controls and PPAR-y levels are significantly lower. Treatment with | | | | | |
| | | Ginsenoside Rg1 in vivo inhibits IκBα phosphorylation, reduces NF-κB nuclear translocation and | | | | | |
| | | upregulates PPAR-γ expression. Ginsenoside Rg1 (G-Rg1) and Ginsenoside Rg2 (G-Rg2) reduce the | | | | | |
| | 压力研究 | escape latencies on the last two training days compared to the Alzheimer's disease (AD) model | | | | | |
| | 体内研究 | group (p<0.05). In the spatial exploration test, the total time spent in the target quadrant and the | | | | | |
| | | number of mice that exactly crossed the previous position of the platform are clearly shorter and | | | | | |
| | | lower, respectively, in the AD model group mice than in the normal control group mice (p<0.01), a | | | | | |
| | | trend that is reversed by treatment with Ginsenoside Rg1 and Ginsenoside Rg2 (Ginsenoside Rg1, | | | | | |
| | | p<0.01; Ginsenoside Rg2, p<0.05). Treatment with Ginsenoside Rg1 and Ginsenoside Rg2 effectively | | | | | |

| | improve cognitive function of the mice that have declined due to AD. Ginsenoside Rg1 and |
|------|--|
| | Ginsenoside Rg2 reduce Aβ1-42 accumulation in APP/PS1 mice. In the Ginsenoside Rg1 and |
| | Ginsenoside Rg2 treated mice, the pathological abnormalities observed in the APP/PS1 mice are |
| | gradually ameliorated. Clear nucleoli and light brown, sparsely scattered Aß deposits are visible. |
| 临床实验 | N/A |

参考文献:

- 1. Li N, et al. J Ginseng Res. 2016,40(1):9-17.
- 2. Wang P, et al. Aust Dent J. 2012,57(2):157-65.
- 3. Zhang L, et al. Oncotarget. 2017,8(33):55384-55393.

包装清单:

| 产品编号 | 产品名称 | 包装 |
|--------------|----------------------|-----------------------------------|
| SM6040-10mM | 人参皂苷 Rg1 (98%, HPLC) | $10\text{mM} \times 0.2\text{ml}$ |
| SM6040-25mg | 人参皂苷 Rg1 (98%, HPLC) | 25mg |
| SM6040-100mg | 人参皂苷 Rg1 (98%, HPLC) | 100mg |
| - | 说明书 | 1份 |

保存条件:

-20℃保存,至少一年有效。固体粉末4℃保存,至少一个月有效。如果溶于非DMSO溶剂,建议分装后-80℃保存,预计6个月内 有效。

注意事项:

- ▶ 本产品可能对人体有一定的毒害作用,请注意适当防护,以避免直接接触人体或吸入体内。
- ▶ 本产品仅限于专业人员的科学研究用,不得用于临床诊断或治疗,不得用于食品或药品,不得存放于普通住宅内。
- ▶ 为了您的安全和健康,请穿实验服并戴一次性手套操作。

使用说明:

- 1. 收到产品后请立即按照说明书推荐的条件保存。使用前可以在2,000-10,000g离心数秒,以使液体或粉末充分沉降至管底后再开盖
- 2. 对于10mM溶液,可直接稀释使用。对于固体,请根据本产品的溶解性及实验目的选择相应溶剂配制成高浓度的储备液(母液)后使
- 3. 具体的最佳工作浓度请参考本说明书中的体外、体内研究结果或其它相关文献,或者根据实验目的,以及所培养的特定细胞和组 织, 通过实验进行摸索和优化。
- 4. 不同实验动物依据体表面积的等效剂量转换表请参考如下网页: https://www.beyotime.com/support/animal-dose.htm

Version 2022.04.25